Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling
about
Biomarkers and Targeted Therapy in Pancreatic CancerGenetics and biology of pancreatic ductal adenocarcinomaTargeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitorsThe Key Role of Calmodulin in KRAS-Driven AdenocarcinomasLong-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.The role of Cdk5 in neuroendocrine thyroid cancerDifferential expression of cell cycle regulators in CDK5-dependent medullary thyroid carcinoma tumorigenesisRegulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.First BRET-based screening assay performed in budding yeast leads to the discovery of CDK5/p25 interaction inhibitors.Oncogenic KRAS signalling in pancreatic cancer.Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft modelsProteomic analysis of the human cyclin-dependent kinase family reveals a novel CDK5 complex involved in cell growth and migrationDiscovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screeningNestin predicts a favorable prognosis in early ampullary adenocarcinoma and functions as a promoter of metastasis in advanced cancer.CDK5 is a major regulator of the tumor suppressor DLC1Genome-wide promoter methylome of small renal masses.The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery.Small-molecule screening of PC3 prostate cancer cells identifies tilorone dihydrochloride to selectively inhibit cell growth based on cyclin-dependent kinase 5 expression.CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis.Bioinformatics Knowledge Map for Analysis of Beta-Catenin Function in Cancer.Phosphorylation of a splice variant of collapsin response mediator protein 2 in the nucleus of tumour cells links cyclin dependent kinase-5 to oncogenesis.Computational identification and modeling of crosstalk between phosphorylation, O-β-glycosylation and methylation of FoxO3 and implications for cancer therapeutics.Insights into the clinical value of cyclin-dependent kinase 5 in glioma: a retrospective study.Cyclin-Dependent Kinase 5 (CDK5) Controls Melanoma Cell Motility, Invasiveness, and Metastatic Spread-Identification of a Promising Novel therapeutic target.Cyclin-dependent kinase 5 activates guanine nucleotide exchange factor GIV/Girdin to orchestrate migration-proliferation dichotomyAchaete-scute homologue-1 (ASH1) stimulates migration of lung cancer cells through Cdk5/p35 pathway.Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-RasCyclin-Dependent Kinase Inhibitors as Anticancer TherapeuticsPhosphoregulation of the RNA-binding protein Hu antigen R (HuR) by Cdk5 affects centrosome function.Targeting STAT3/miR-21 axis inhibits epithelial-mesenchymal transition via regulating CDK5 in head and neck squamous cell carcinomaRetinoic Acid Induces Apoptosis of Prostate Cancer DU145 Cells through Cdk5 OveractivationMicroRNAs at the human 14q32 locus have prognostic significance in osteosarcoma.The BEAF insulator regulates genes involved in cell polarity and neoplastic growth.Inhibition of endothelial Cdk5 reduces tumor growth by promoting non-productive angiogenesis.Low Expression of CDK5 and p27 Are Associated with Poor Prognosis in Patients with Gastric Cancer.Evaluation and clinical significance of cyclin-dependent kinase5 expression in cervical lesions: a clinical research study in Guangxi, ChinaCDK5 is essential for TGF-β1-induced epithelial-mesenchymal transition and breast cancer progression.Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunityCyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1α: a novel approach for inhibiting angiogenesis in hepatocellular carcinoma.
P2860
Q26752755-4CE39C5C-2218-4390-B9B2-AD848D97B606Q26765438-800AE88D-08E4-458F-923C-674A62F8E1CAQ26827580-CA828884-E730-4B84-A1C2-69A3E6B1498FQ27021883-325BC853-6989-4855-9252-0CFACAEC0D68Q27853310-84685B6D-5887-4079-BE95-9CEACCD2210AQ28392185-39599B88-5CF5-43EA-8983-10156B929F93Q28397935-0462CE42-5F41-40E7-AEBA-EA21000A2AB6Q30424897-C53C9382-3737-446F-93C7-4B52526160BDQ33779805-C463A590-B2AC-44D8-8373-573B1C9E9BCEQ33935146-7BD9739E-2729-44E5-B560-9D875F3DF91EQ34113460-93AD978E-21C7-4A2F-A5D1-CE04DEA433ACQ34201623-55E7FE7F-D593-4819-BB52-1C7CEA1235DDQ34468337-3D82BC84-F446-4AC5-B5BF-AA9E8443A408Q34625383-6DC25CF4-E54E-4812-981A-7E6AB4F5EF0EQ34626101-1DA1CA9D-8356-4170-92B8-90BD756B8516Q34656836-C8BB8E18-FDDF-40EC-A411-D2D8482D59CEQ35035170-DC3BA903-7AE1-405F-8323-41D1BA5BEC98Q35083727-02BB98B9-D5DC-4463-860B-406FE31C0A1AQ35171132-56ED86D3-07BC-4277-A40A-5AA4550EFEAEQ35683173-A02C2883-AE71-460A-B81C-386B949F6811Q35824062-449EC992-4DD1-4CFE-BCFE-79BA602D0310Q35837176-2DC1F112-9A6A-4A32-8206-07B6430F8CEBQ35865318-F0F4DFDF-694B-4829-BE24-045C8AABC7C6Q35886193-BF304F14-732D-4D8B-A85A-CAF4C5CF4D4DQ36037996-8CC8E398-944B-498C-96CE-8D37A4736F3CQ36055684-BC74D5C2-EE35-4546-BE83-CEAA5243F5CCQ36127961-B2106180-CBD7-41A4-83A5-C090337DDCA8Q36182661-8730EA8B-4E53-4966-8CE8-752D6A0A033AQ36186117-FA963979-D3DE-487E-A260-EEB7FC8BE527Q36234835-141401EB-3727-4105-AFC9-9FDE45098FC3Q36393733-D50CE6B8-302B-4483-BFCF-CF67B6CDCCCBQ36495910-1DF3EAC4-DE37-4797-8B8D-ED4088371B0AQ36594516-5C31190F-6433-463C-85DA-514466A44DCFQ36610893-A25AFC74-B961-4BEA-8D99-3EA960085C88Q36905854-F4F859AE-A92E-4C20-ABE0-ABBBB653B1FBQ37015708-F494D172-A8A0-4F43-A652-E7E432BB1BC6Q37089878-E0F25C98-0BC8-48FA-B0B4-1E45A6D5F40EQ37229083-1D58A874-3EE1-4A74-9935-9A92A5537A1CQ37313139-E5E4D68A-1259-4CAE-925B-D6025F586122Q37317180-80AD7B6A-B785-44C6-8834-73140E18D815
P2860
Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Inhibiting the cyclin-dependen ...... ppression of Ras-Ral signaling
@ast
Inhibiting the cyclin-dependen ...... ppression of Ras-Ral signaling
@en
Inhibiting the cyclin-dependen ...... ppression of Ras-Ral signaling
@nl
type
label
Inhibiting the cyclin-dependen ...... ppression of Ras-Ral signaling
@ast
Inhibiting the cyclin-dependen ...... ppression of Ras-Ral signaling
@en
Inhibiting the cyclin-dependen ...... ppression of Ras-Ral signaling
@nl
prefLabel
Inhibiting the cyclin-dependen ...... ppression of Ras-Ral signaling
@ast
Inhibiting the cyclin-dependen ...... ppression of Ras-Ral signaling
@en
Inhibiting the cyclin-dependen ...... ppression of Ras-Ral signaling
@nl
P2093
P2860
P50
P1433
P1476
Inhibiting the cyclin-dependen ...... ppression of Ras-Ral signaling
@en
P2093
Anjali Mishra
Barry D Nelkin
Christopher J Strock
Douglas W Ball
Georg Feldmann
Savita Bisht
P2860
P304
P356
10.1158/0008-5472.CAN-09-1107
P407
P577
2010-05-18T00:00:00Z